Abstract-Nitric oxide (NO) is an essential vasodilator. In vascular diseases, oxidative stress attenuates NO signaling by both chemical scavenging of free NO and oxidation and downregulation of its major intracellular receptor, the ␣ heterodimeric heme-containing soluble guanylate cyclase (sGC). Oxidation can also induce loss of the heme of sGC, as well as the responsiveness of sGC to NO. sGC activators such as BAY 58-2667 bind to oxidized/heme-free sGC and reactivate the enzyme to exert disease-specific vasodilation. Here, we show that oxidation-induced downregulation of sGC protein extends to isolated blood vessels. Mechanistically, degradation was triggered through sGC ubiquitination and proteasomal degradation. The heme-binding site ligand BAY 58-2667 prevented sGC ubiquitination and stabilized both ␣ and  subunits. Collectively, our data establish oxidation-ubiquitination of sGC as a modulator of NO/cGMP signaling and point to a new mechanism of action for sGC activating vasodilators by stabilizing their receptor, oxidized/heme-free sGC. O ne major risk factor for the development of cardiovascular diseases, such as coronary heart disease, stroke, and myocardial infarction, is an imbalance of the production and elimination of reactive oxygen species, also termed as oxidative stress. [1][2][3] As a consequence, the nitric oxide (NO)/ cGMP signaling cascade is impaired, eg, through the excessive production of superoxide, which reacts with NO in a diffusion-limited reaction, yielding peroxynitrite. 4 The biological impact of NO scavenging is further aggravated by the progressive inhibition and downregulation of the NO receptor soluble guanylate cyclase (sGC). [5][6][7][8][9] Circumstantial evidence has implicated proteasomal pathways in this downregulation of sGC. 10 -12 Conversely, a novel class of sGC activators, represented by BAY 58-2667, are potentiated under oxidative stress conditions and represent thus an entirely new diseasespecific vasodilator class. 13 sGC is a heterodimer consisting of an ␣ and a Fe 2ϩ /hemecontaining  subunit that complexes NO with high affinity and specificity. 14 Binding of NO to the Fe 2ϩ /heme results in allosteric activation of the enzyme and enhanced conversion of GTP into the vasorelaxant and antiproliferative second messenger cGMP. 14,15 In vitro experiments have demonstrated that oxidation of sGC heme to its ferric (Fe 3ϩ ) form by the sGC inhibitor 1H-[1,2,4]-oxadiazolo [3,4-a]quinoxalin-1-one (ODQ) attenuates NO-mediated cGMP production, suggesting that the ferro (Fe 2ϩ ) form of sGC is crucial for activation by NO. 16 -18 In addition, studies with primary endothelial and smooth muscle cells have revealed that, within 24 hours, ODQ causes a dramatic decrease in sGC protein levels. 13 Similar results were obtained with other oxidizing compounds such as methylene blue or the peroxynitrite donor 1,3-morpholino-sydnonimine hydrochloride (SIN-1), indicating that oxidative stress triggers downregulation of sGC protein levels. 13 At present, the molecular mechanisms under...
BackgroundDevelopment of polyneuropathy (PNP) under treatment for tuberculosis (TB), including isoniazid (INH), is a highly relevant adverse drug effect. The NAT2 acetylation status is a predictor of potential toxic effects of INH. The question as to whether individual risk stratification by genotyping is useful to avoid suffering of patients and to lower costs for the health care system is of considerable clinical importance.Case PresentationAfter drug treatment for TB, including INH, a 23-year-old man developed severe PNP. During the treatment, laboratory results have been indicating incipient liver and renal injury. Later, molecular genetic analyses were performed and revealed a variation in the NAT2 gene and the c1/c2 genotype of the CYP2E1 gene, both described to contribute to an elevated risk for anti-tuberculostatic-induced liver damages (ATIL).ConclusionThe combination of metabolizer genotypes should be taken into account as a cause for toxic effects and the development of PNP. Individual genotyping, performed before medication or at least if an elevation of liver parameters is observed, may reduce the risk of severe cases of PNP by early adjustment of treatment. Our case study indicates that evaluation of individual risk stratification with systematic pharmacogenetic genotyping of metabolizer gene combinations in the context of TB treatment should be addressed in clinical studies with larger cohorts.
Oxidative stress attenuates the NO-cGMP pathway, e.g. in the vascular system, through scavenging of free NO radicals by superoxide O 2•-, by inactivation of soluble guanylyl cyclase (sGC) via oxidation of its central Fe 2+ ion, and by down-regulation of sGC protein levels. While the former pathways are well established, the molecular mechanisms underlying the latter are still obscure. Using oxidative sGC inhibitor ODQ we demonstrate rapid down-regulation of sGC protein in mammalian cells. Coincubation with proteasomal inhibitor MG132 results in accumulation of ubiquitinated sGC whereas sGC activator BAY 58-2667 prevents ubiquitination. ODQ-induced down-regulation of sGC is mediated through selective ubiquitination of its b subunit, and BAY 58-2667 abrogates this effect. Ubiquitination of sGC-b is dramatically enhanced by E3 ligase CHIP. Our data indicate that oxidative stress promotes ubiquitination of sGC b subunit through E3 ligase CHIP, and that sGC activator 58-2667 reverts this effect, most likely through stabilization of the heme-free b subunit. Thus the deleterious effects of oxidative stress can be counter-balanced by an activator of a key enzyme of vascular homeostasis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.